SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) — MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule.
The company’s Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robustly, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomized, double-blind, placebo-controlled trial that is expected to enroll 300 hospitalized adult participants with schizophrenia experiencing acute exacerbation of psychosis.
“The accelerated enrollment pace in the ZEPHYR trial allows us to narrow our timing guidance to the third quarter of 2026,” said Chris Kroeger, co-Founder and Chief Executive...
iBio Announces $26 Million Private Placement
Written by Customer Service on . Posted in Public Companies.
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) — iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality institutional investors for a private placement (“PIPE”) financing that is expected to result in gross proceeds of approximately $26 million to the Company before placement agent fees and offering expenses. The offering is expected to close on or about January 13, 2026, subject to customary closing conditions.
The financing was led by Frazier Life Sciences and included participation from other existing investors.
iBio intends to use the net proceeds received from the offering to advance its preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and the myostatin...
VR Upsizes Brokered Private Placement Led by Centurion One Capital to $1,500,000
Written by Customer Service on . Posted in Public Companies.
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, British Columbia, Jan. 09, 2026 (GLOBE NEWSWIRE) — VR Resources Limited (“VR” or the “Company”, TSXV: VRR) announces that due to significant investor demand, it has increased the size of its previously announced brokered private placement offering (the “Offering”). Pursuant to the upsize, the Company will issue up to 9,375,000 units (the “Units) for aggregate gross proceeds of $1,500,000. Centurion One Capital Corp. (the “Lead Agent”) is acting as lead agent and sole bookrunner. In addition, the Company has agreed to grant to the Lead Agent an option exercisable, in whole or in part, at the sole discretion of the Lead Agent, to sell up to $500,000 in additional Units pursuant to the Offering.
As previously disclosed, each...
Aurora Mobile Partners with Xiaoe to Enhance Interaction Efficiency and Support Sustainable Growth in Private Domain Ecosystems
Written by Customer Service on . Posted in Public Companies.
SHENZHEN, China, Jan. 09, 2026 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that it has entered into a strategic partnership with Xiaoe Inc. (“Xiaoe”) to integrate its intelligent push notification solution, JPush, into Xiaoe’s flagship private domain SaaS platform.
When operating private domains, a platform’s value lies not only in providing operational tools but also in enabling continuous and effective interactions between merchants and users. Missed service alerts and delayed notification can limit service coverage and weaken user engagement. Xiaoe acts as a bridge between brands and users, helping countless merchants build their digital presence. Recognizing the critical role that...
Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update
Written by Customer Service on . Posted in Public Companies.
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time
Receives confirmation from FDA that Agency’s review of Anaphylm NDA application is ongoing and no final FDA decision has been made
Progresses global regulatory expansion activities in Canada, Europe, and the United Kingdom for Anaphylm
Unaudited cash and cash equivalents of approximately $120 million as of December 31, 2025WARREN, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today provided an update on the regulatory approval of Anaphylm™ and...
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
Written by Customer Service on . Posted in Public Companies.
DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in therapies for patients with elevated triglycerides (TG) and shared its perspective on how these developments stand to shape patient access and treatment strategies. Specifically, new therapies for these patients are likely to expand the use of existing, proven options over time, including Amarin’s VASCEPA®/VAZKEPA® (icosapent ethyl), an effective, safe, oral therapy that has been prescribed more than 25 million times to patients globally. In addition, through its approved indication for severe hypertriglyceridemia (sHTG), which is defined as TG ≥500 mg/dL, as well as strong clinical evidence, affordability, and broad...
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025
Received more than 2,800 unique patient prescriptions since launch in June 2025
Generated more than $30 million of positive cash flow during the fourth quarter 2025MORRISVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced preliminary, unaudited full-year 2025 net product sales of YUTREPIA™ (treprostinil) inhalation powder, as well as updates on the commercial launch and the clinical pipeline. These updates will be discussed during Liquidia’s participation in the 44th Annual J.P. Morgan Healthcare...
Form 8.5 (EPT/RI) – PPHE Hotel Group Ltd
Written by Customer Service on . Posted in Mergers And Acquisitions.
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)
1. KEY INFORMATION(a) Name of exempt principal trader:
Shore Capital Stockbrokers Ltd(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree
PPHE Hotel Group Ltd(c) Name of the party to the offer with which exempt principal trader is connected:
PPHE Hotel Group Ltd(d) Date dealing undertaken:
08 January 2026(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?
No2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
(a) Purchases and salesClass...
RadNet, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference January 14th, 2026
Written by Customer Service on . Posted in Public Companies.
LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, Mark Stolper, Executive Vice President and Chief Financial Officer, Dr. Gregory Sorensen, Executive Vice President and Chief Strategy Officer and Kees Wesdorp, President & CEO of RadNet Digital Health will be presenting at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. PST.
A live webcast of RadNet’s presentation can be accessed through the following link, https://jpmorgan.metameetings.net/events/healthcare26/sessions/317344-radnet-inc/webcast?gpu_only=true&kiosk=true...
Pandora expects to deliver 6% organic growth and around 24% EBIT margin in 2025
Written by Customer Service on . Posted in Public Companies.
Pandora today announced preliminary and unaudited results for 2025. The company is expected to deliver organic growth of 6% for 2025, marginally below the prior guidance of 7-8%. Group EBIT margin for 2025 is expected to be in line with guidance of around 24%. Pandora will, as already communicated, announce audited full-year 2025 results on 5 February, 2026.
The top-line performance reflects a year marked by a generally weak consumer sentiment, with North America being particularly impacted in Q4 2025. The bottom-line performance demonstrates strong gross margins and cost discipline which partially offset significant external headwinds from commodity prices, foreign exchange rates, and tariffs.
Berta de Pablos-Barbier was appointed as President & CEO of Pandora on 1 January, 2026. On 5 February, alongside the full-year results, she...
